The ixCELL-DCM phase 2b clinical trial is evaluating ixmyelocel-T for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company expects enrollment to be completed in the second half of 2014.

Last year, Aegerion received orphan drug designation from Japan's Ministry of Health, Labour and Welfare for lomitapide. The company hopes to submit the filing for marketing approval of Lomitapide in Japan as early as mid-2015.

AEGR closed Wednesday's trading 5.66% higher at $44.21.

AngioDynamics Inc. (ANGO: Quote) has turned a profit in its fiscal 2014 third quarter as sales grew 8 percent, reflecting continued market acceptance of its innovative products.

Looking forward to fiscal year 2014, the company now expects sales to range between $351 million to $355 million, up from its prior forecast of $349 million to $353 million.

DelMar Pharmaceuticals Inc. (DMPI.OB) said Wednesday that new data from its ongoing phase I/II clinical trial with VAL-083 in the treatment of refractory glioblastoma multiforme has revealed that the compound is well tolerated, with no drug-related serious adverse events have been detected in 26 patients treated to date in the study.

The company noted that dose limiting toxicity has not been reached after fifth cohort and that the sixth cohort has been fully enrolled.